abiraterone has been researched along with Thyroid Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Monneret, C | 1 |
| Beckmann, L; Bender, R; Lange, S | 1 |
1 review(s) available for abiraterone and Thyroid Neoplasms
| Article | Year |
|---|---|
[Four new drugs on the market: abiraterone, belatacept, vandetanib and fidaxomycine].
Topics: Abatacept; Aminoglycosides; Androstenes; Androstenols; Anti-Bacterial Agents; Antineoplastic Agents; Clostridioides difficile; Clostridium Infections; Enzyme Inhibitors; Fidaxomicin; Humans; Immunoconjugates; Immunosuppressive Agents; Male; Piperidines; Prostatic Neoplasms; Quinazolines; Thyroid Neoplasms | 2013 |
1 other study(ies) available for abiraterone and Thyroid Neoplasms
| Article | Year |
|---|---|
Biometrical issues in the analysis of adverse events within the benefit assessment of drugs.
Topics: Adverse Drug Reaction Reporting Systems; Androstenes; Antineoplastic Agents; Clinical Trials as Topic; Drug Approval; Drug Industry; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Germany; Humans; Male; Piperidines; Prostatic Neoplasms; Quinazolines; Survival Rate; Thyroid Neoplasms | 2016 |